Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness
Summary of Adverse Effects of Pharmacological Interventions
Tolerability of pharmacological interventions, represented by the rate of discontinuation of treatment due to adverse effects, includes:
No statistically significant difference from placebo (darifenacin, tolterodine) and less than 10 percent difference in the rate from placebo (discontinuations per 1,000: solifenacin, 10; trospium, 20; fesoterodine, 30; oxybutynin, 63). The strength of evidence for these findings is high.
Dry mouth is the most common adverse effect (100 per 1,000 treated patients), followed by constipation (47 to 83 per 1,000 treated patients).
Dry eye, blurred vision, and dyspepsia are less frequent, with fewer than 50 events per 1,000 treated patients, with the exception of dyspepsia with oxybutynin at 80 per 1,000 treated patients.
Keywords: urinary incontinence | stress incontinence | urge incontinence | urgency incontinence | mixed incontinence | tolerability | pharmacological | darifenacin | tolterodine | solifenacin | trospium | fesoterodine | oxybutynin | dyspepsia | dry mouth | adverse effect
- Shamliyan T, Wyman J, Sainfort F, et al. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Comparative Effectiveness Review No. 36 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 11(12)-EHC074-EF. Available at www.effectivehealthcare.ahrq.gov/ui.cfm.
Your slide tray is being processed.